Citations

Clear

533 citation(s) found for "Mielke, Michelle M".

Blood‐based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic
Lista, Simone , Vanderstichele, Hugo, Posner, Holly, Hall, James , Johnson, Leigh , Fong, Y L, Luthman, Johan, Jeromin, Andreas, Batrla‐Utermann, Richard, Villarreal, Alcibiades E. , Britton, Gabrielle B. , Snyder, Peter J. , Henriksen, Kim , Grammas, Paula , Gupta, Veer Bala , Martins, Ralph N. , Hampel, Harald , Area, Biofluid Based Biomarker Professional Interest, O’Bryant, Sid E. , Mielke, Michelle M. , Rissman, Robert A. , Zetterberg, Henrik , Lewczuk, Piotr , Area, Biofluid Based Biomarker Professional Interest

Mayo Clinic

Alzheimer's & Dementia | November 18, 2016 | Volume: 13 | Issue: 1 | Pages: 45-58

10.1016/j.jalz.2016.09.014 | PMID 27870940 Get It

AbstractThe last decade has seen a substantial increase in research focused on the identification of blood‐based biomarkers that have utility in Alzheimer's disease (AD). Blood‐based biomarkers have significant advantages of being time‐ and cost‐efficient as well as reduced invasiveness and increased patient acceptance. Despite these advantages and increased research efforts, the field has been hampered by lack of reproducibility and an unclear path for moving basic discovery toward clinical utilization. Here we reviewed the recent literature on blood‐based biomarkers in AD to provide a current state of the art. In addition, a collaborative model is proposed that leverages academic and industry strengths to facilitate the field in moving past discovery only work and toward clinical use. Key resources are provided. This new public‐private partnership model is intended to circumvent the traditional handoff model and provide a clear and useful paradigm for the advancement of biomarker science in AD and other neurodegenerative diseases.
Timing of Physical Activity, Apolipoprotein E ε 4 Genotype, and Risk of Incident Mild Cognitive Impairment
Pink, Anna , Roberts, Rosebud O., Stokin, Gorazd B. , Mielke, Michelle M. , Spangehl, Kathleen A., Bartley, Mairead M. , Christianson, Teresa J., Petersen, Ronald C. , Geda, Yonas E. , Krell-Roesch, Janina, Christianson, Teresa J H, Krell‐Roesch, Janina , Knopman, David S. , Mielke, Michelle M , Geda, Yonas E , Stokin, Gorazd

Mayo Clinic

Journal of the American Geriatrics Society | November 1, 2016 | Volume: 64 | Issue: 12 | Pages: 2479-2486

10.1111/jgs.14402 | PMID 27801933 Get It

Objectives To investigate the timing (mid‐ vs late life) of physical activity, apolipoprotein ( APO )E ε 4, and risk of incident mild cognitive impairment ( MCI ). Design Prospective cohort study. Setting Mayo Clinic Study of Aging (Olmsted County, MN ). Participants Cognitively normal elderly adults (N = 1,830, median age 78, 50.2% female). Measurements Light, moderate, and vigorous physical activities in mid‐ and late life were assessed using a validated questionnaire. An expert consensus panel measured MCI based on published criteria. Cox proportional hazards models were used to calculate hazard ratios ( HR s) and 95% confidence intervals ( CI s) with age as a time scale after adjusting for sex, education, medical comorbidity, and depression. Results Light ( HR = 0.58, 95% CI = 0.43–0.79) and vigorous ( HR = 0.78, 95% CI = 0.63–0.97) physical activity in midlife were associated with lower risk of incident MCI . The association between moderate activity and incident MCI was not significant ( HR = 0.85, 95% CI = 0.67–1.09). In late life, light ( HR = 0.75, 95% CI = 0.58–0.97) and moderate ( HR = 0.81, 95% CI = 0.66–0.99) but not vigorous physical activity were associated with lower risk of incident MCI . A synergistic interaction was also observed between mid‐ and late‐life activity in reducing risk of incident MCI . Furthermore, APOE ε 4 carriers who did not exercise had a higher risk of incident MCI than noncarriers who reported physical activity. Conclusion Physical activity reduced the risk of incident MCI . Exercising in mid‐ and late life had an additive synergistic interaction in reducing the risk of MCI .
Incidence and time trends of drug‐induced parkinsonism: A 30‐year population‐based study
Savica, Rodolfo , Grossardt, Brandon R. , Bower, James H., Ahlskog, J. Eric , Rocca, Walter A. , Mielke, Michelle M. , Grossardt, Brandon R

Mayo Clinic

Movement Disorders | October 25, 2016 | Volume: 32 | Issue: 2 | Pages: 227-234

10.1002/mds.26839 | PMID 27779780 Get It

ABSTRACT Background Epidemiological studies of drug‐induced parkinsonism remain limited. Objectives To investigate the incidence and time trends of drug‐induced parkinsonism over 30 years in a geographically defined American population. Methods We used the medical records‐linkage system of the Rochester Epidemiology Project to identify all persons in Olmsted County, Minnesota, who received a screening diagnostic code for parkinsonism from 1976 through 2005. A movement disorders specialist reviewed the complete medical records of each person to confirm the presence of drug‐induced parkinsonism associated with dopamine‐blocking or dopamine‐depleting medications. Results Among 906 incident cases of parkinsonism from 1976 to 2005, 108 persons had drug‐induced parkinsonism (11.9%). The average annual incidence rate of drug‐induced parkinsonism was 3.3 per 100,000 person‐years, was higher in women, and increased with older age. Drug‐induced parkinsonism was the fifth‐most common type of parkinsonism overall; however, it was the most common type among persons younger than age 40 years. Typical antipsychotic drugs were the most common class of drugs associated with parkinsonism, whereas atypical antipsychotic drugs were rarely involved. The incidence rate of drug‐induced parkinsonism decreased 32.0% per decade (relative risk = 0.68; 95% confidence interval: 0.49–0.94) and 68.6% over the 30 years of the study. The decrease was similar in men (65.2%) and women (69.4%); however, the trend was significant only in women. Conclusions The incidence of drug‐induced parkinsonism increased with older age and was higher in women at all ages. Typical antipsychotic drugs were the most common cause. The incidence of drug‐induced parkinsonism decreased over the 30 years of the study because of changes in drug use. © 2016 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
P2‐178: Amyloid‐B, Neuropsychiatric Symptoms and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of Aging
Pink, Anna , Roberts, Rosebud O., Vemuri, Prashanti, Christianson, Teresa J., Lowe, Val J. , Petersen, Ronald C. , Krell‐Roesch, Janina , Stokin, Gorazd B. , Mielke, Michelle M. , Jack, Clifford R. , Boeve, Bradley F. , Geda, Yonas E.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_14 | Pages: No page available

10.1016/j.jalz.2016.06.1345 Get It

O2‐05‐04: Resilience Factors for Amyloid Deposition and Neurodegeneration are Different
Lesnick, Timothy G. , Przybelski, Scott A. , Roberts, Rosebud O., Lowe, Val J. , Petersen, Ronald C. , Vemuri, Prashanthi , Knopman, David S. , Machulda, Mary M. , Mielke, Michelle M. , Geda, Yonas E. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_5 | Pages: No page available

10.1016/j.jalz.2016.06.420 Get It

P2‐276: Decreased Posterior Gray Matter Volumes in Women who Experienced Hypertensive Pregnancies and Have Late‐Life Hypertension
Raman, Mekala R., Tosakulwong, Nirubol , Preboske, Gregory M., Fields, Julie A. , Miller, Virginia M. , White, Wendy , Mielke, Michelle M. , Jack, Clifford R. , Garovic, Vesna D. , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_15 | Pages: No page available

10.1016/j.jalz.2016.06.1536 Get It

O2‐08‐01: Av1451 Pet Imaging in the Spectrum of Alzheimer's Disease from Clinically Normal to Dementia
Wiste, Heather J. , Petersen, Ronald C. , Roberts, Rosebud O., Weigand, Stephen D. , Graff‐Radford, Jonathan , Lowe, Val J. , Knopman, David S. , Jack, Clifford R. , Boeve, Bradley F. , Kantarci, Kejal , Jones, David T. , Mielke, Michelle M. , Vemuri, Prashanthi , Machulda, Mary M.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_5 | Pages: No page available

10.1016/j.jalz.2016.06.436 Get It

P3‐268: Cerebral Amyloid Deposition is Associated with Poorer Gait in Cognitively Normal Late‐Middle Aged Individuals: the Mayo Clinic Study of Aging
Savica, Rodolfo , Hagen, Clinton E., Roberts, Rosebud O., Petersen, Ronald C. , Wennberg, Alexandra , Knopman, David S. , Jack, Clifford R. , Mielke, Michelle M.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_19 | Pages: No page available

10.1016/j.jalz.2016.06.1931 Get It

P3‐152: Levels of TAU Protein in Plasma are Associated with Neurodegeneration and Cognitive Function in a Population‐Based Elderly Cohort
Airey, David , Hagen, Clinton E., Roberts, Rosebud O., Petersen, Ronald C. , Dage, Jeffrey L. , Wennberg, Alexandra , Knopman, David S. , Machulda, Mary M. , Jack, Clifford R. , Mielke, Michelle M.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_18 | Pages: No page available

10.1016/j.jalz.2016.06.1812 Get It

IC‐P‐080: Decreased Posterior Gray Matter Volumes in Women Who Experienced Hypertensive Pregnancies and Have Late‐Life Hypertension
Raman, Mekala R., Tosakulwong, Nirubol , Preboske, Gregory M., Fields, Julie A. , Miller, Virginia M. , White, Wendy , Mielke, Michelle M. , Jack, Clifford R. , Garovic, Vesna D. , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_2 | Pages: No page available

10.1016/j.jalz.2016.06.109 Get It